Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (1-10 of 242) with videos related to

Pageof 25
Sort By:
Klinische Padiatrie|November 7, 2018
Till Milde, Olaf Witt
Cancer Letters|March 24, 2009
HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapyOlaf Witt, Ralph Lindemann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|March 27, 2009
Pediatric gliomasStefan Pfister, Olaf Witt
Neuro-Oncology|December 8, 2025
Response to letter from Dr. AveryKarsten Nysom, Olaf Witt, Darren Hargrave
Cells|April 28, 2015
HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor EntitiesEmily Koeneke, Olaf Witt, Ina Oehme
CNS Oncology|July 24, 2014
Targeting of histone deacetylases in brain tumorsJonas Ecker, Olaf Witt, Till Milde
Biometrical Journal. Biometrische Zeitschrift|January 8, 2014
Adaptive designs with arbitrary dependence structureRene Schmidt, Andreas Faldum, Olaf Witt, et al.
Autophagy|October 23, 2013
Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomasIna Oehme, Marco Lodrini, Nathan R Brady, et al.
Med (New York, N.Y.)|August 13, 2022
Pediatric precision oncology-Time for clinical prime timeStefan M Pfister, Olaf Witt, David T W Jones
Cancer Letters|October 1, 2008
HDAC family: What are the cancer relevant targets?Olaf Witt, Hedwig E Deubzer, Till Milde, et al.
Pageof 25

Showing results (1-10 of 242) with videos related to

Sort By:
Pageof 25
Klinische Padiatrie|November 7, 2018
Till Milde, Olaf Witt
Cancer Letters|March 24, 2009
HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapyOlaf Witt, Ralph Lindemann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|March 27, 2009
Pediatric gliomasStefan Pfister, Olaf Witt
Neuro-Oncology|December 8, 2025
Response to letter from Dr. AveryKarsten Nysom, Olaf Witt, Darren Hargrave
Cells|April 28, 2015
HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor EntitiesEmily Koeneke, Olaf Witt, Ina Oehme
CNS Oncology|July 24, 2014
Targeting of histone deacetylases in brain tumorsJonas Ecker, Olaf Witt, Till Milde
Biometrical Journal. Biometrische Zeitschrift|January 8, 2014
Adaptive designs with arbitrary dependence structureRene Schmidt, Andreas Faldum, Olaf Witt, et al.
Autophagy|October 23, 2013
Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomasIna Oehme, Marco Lodrini, Nathan R Brady, et al.
Med (New York, N.Y.)|August 13, 2022
Pediatric precision oncology-Time for clinical prime timeStefan M Pfister, Olaf Witt, David T W Jones
Cancer Letters|October 1, 2008
HDAC family: What are the cancer relevant targets?Olaf Witt, Hedwig E Deubzer, Till Milde, et al.
Pageof 25